SpringWorks Therapeutics (SWTX) announced that data from the pivotal, Phase 2b ReNeu trial of mirdametinib, an investigational MEK inhibitor, ...

SpringWorks Therapeutics (SWTX) announced that three abstracts from the pivotal Phase 2b ReNeu trial of mirdametinib, an investigational MEK ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in ...

Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients with anaplastic thyroid cancer.

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the ...

An analysis of SpringWorks Therapeutics, Inc., including recent FDA approval, promising sales, and future funding for ...

Verastem Oncology submits NDA to US FDA for avutometinib plus defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer: Boston Monday, November 4, 2024, 14:00 Hrs ...

Q3 2024 Earnings Call Transcript October 30, 2024Day One Biopharmaceuticals, Inc. beats earnings expectations.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...